Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
HemaSphere · 2025-11 · 9 (11)
DOI: 10.1002/hem3.70260 ↗Kurz gefasst
Fachartikel in der Zeitschrift HemaSphere, online erschienen am 25.11.2025. Verfasst von Niels W C J van de Donk und 39 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The treatment landscape of heavily pretreated relapsed/refractory MM has changed considerably in recent years with the introduction of novel BCMA‐ and GPRC5D‐directed immunotherapies, including CAR T‐cell therapy, bispecific antibodies (BsAbs), and antibody‐drug conjugates (ADCs). Treatment selection and sequencing become increasingly complex with the broad range of therapeutic options. In this review, the European Myeloma Network provides recommendations on how to best incorporate these novel therapies into the present treatment landscape using current evidence. The optimal treatment sequence depends on various patient‐ and tumor‐related features, but also reimbursement and availability issues. In addition, mechanisms underlying relapse (e.g., antigen loss, reduced T‐cell fitness, or outgrowth of T‐cell resistant clones) dictate the efficacy of sequential BCMA‐ or GPRC5D‐directed immunotherapy. BCMA‐targeting BsAbs and ADCs should preferably be avoided prior to CAR T‐cell therapy, as some studies have shown that these agents negatively influence clinical outcomes after CAR T‐cell therapy. Therefore, we recommend the selection of CAR T‐cell therapy first, and BsAbs and/or belamaf later in the disease course, if patients are eligible for CAR T‐cell therapy and in case CAR T‐cell therapy is available within a short time frame. However, bridging therapy with GPRC5D‐directed BsAbs (initiation after apheresis) can be considered to significantly reduce tumor burden, because this was shown to improve the efficacy of consecutive BCMA‐directed CAR T‐cell therapy. Sequential treatment with agents targeting the same antigen, but with different modes of action, is feasible, but several studies have demonstrated that target switch is a more effective strategy. In addition, there is increasing evidence indicating that the efficacy of sequential use of BsAbs can be improved by creating a BsAb‐free interval.
Autor:innen und Institutionen
- Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands.
- Cancer Center Amsterdam Cancer Biology and Immunology Amsterdam The Netherlands.
- Department of Hematology University Hospital Hôtel-Dieu Nantes France.
- Cancer Center Clinica Universidad de Navarra CIMA, IDISNA, CIBERONC Pamplona Spain.
- Cancer Research Center University Hospital of Salamanca, IBSAL Salamanca Spain.
- Department of Clinical Therapeutics, School of Medicine National and Kapodistrian University of Athens Athens Greece.
ORCID-Profile: Niels W C J van de Donk, Meletios A Dimopoulos, Martin Kaiser, Charlotte L B M Korst, Carlos Fernandez de Larrea, Paula Rodriguez-Otero, Marin Kortüm
Zitieren
APA
van de Donk, N. W. C. J., Moreau, P., San-Miguel, J. F., Mateos, M. V., Dimopoulos, M. A., Zweegman, S., Gay, F., Engelhardt, M., Mina, R., Zamagni, E., Delforge, M., Beksac, M., Spencer, A., Schjesvold, F., Driessen, C., Kaiser, M., Perrot, A., Wäsch, R., Korst, C. L. B. M., …, & EMN Guidelines Committee (2025). Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network. HemaSphere, 9(11). https://doi.org/10.1002/hem3.70260
Vancouver
van de Donk NWCJ, Moreau P, San-Miguel JF, Mateos MV, Dimopoulos MA, Zweegman S, et al. Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network. HemaSphere. 2025;9(11). doi:10.1002/hem3.70260
BibTeX
@article{vandeDonk2025,
author = {van de Donk, Niels W C J and Moreau, Philippe and San-Miguel, Jesus F and Mateos, Maria-Victoria and Dimopoulos, Meletios A and Zweegman, Sonja and Gay, Francesca and Engelhardt, Monika and Mina, Roberto and Zamagni, Elena and Delforge, Michel and Beksac, Meral and Spencer, Andrew and Schjesvold, Fredrik and Driessen, Christoph and Kaiser, Martin and Perrot, Aurore and Wäsch, Ralph and Korst, Charlotte L B M and Broijl, Annemiek and Touzeau, Cyrille and Manier, Salomon and Hajek, Roman and Bila, Jelena and Seval, Guldane C and O'Dwyer, Michael and Ludwig, Heinz and Fernandez de Larrea, Carlos and Popat, Rakesh and Musto, Pellegrino and Rodriguez-Otero, Paula and Yong, Kwee and Kortüm, Marin and Rasche, Leo and Terpos, Evangelos and Raab, Marc S and Boccadoro, Mario and Sonneveld, Pieter and Einsele, Hermann and EMN Guidelines Committee, EMN Guidelines Committee},
title = {Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network},
journal = {HemaSphere},
year = {2025},
volume = {9},
number = {11},
doi = {10.1002/hem3.70260}
}
EUVIMED